Science

Scientists Target 'Undruggable' Pancreatic Cancer Protein, Nearly Double Survival

New drug daraxonrasib successfully attacks KRAS mutations that drive most pancreatic tumors, reducing death risk by 60%.

Scientists Target 'Undruggable' Pancreatic Cancer Protein, Nearly Double Survival
Read the full reporting at ScienceDaily Top.

Originally reported by ScienceDaily Top.

pancreatic cancer KRAS protein daraxonrasib targeted therapy clinical trial oncology